



Evolving Digital Health into AI-Powered Care

Sophie Dubois

Asst Professor

Abstract

The rapid evolution of digital health technologies has laid the foundation for a transformative shift toward artificial intelligence (AI)–driven healthcare systems. While early digital health solutions primarily focused on data digitization, connectivity, and remote care delivery, recent advancements in AI have enabled more intelligent, adaptive, and predictive models of care. This transition represents a paradigm shift from reactive and standardized healthcare toward proactive, personalized, and precision-driven interventions. AI-driven care leverages machine learning algorithms, big data analytics, and real-time clinical decision support systems to enhance diagnostic accuracy, optimize treatment pathways, and improve patient outcomes. However, the integration of AI into healthcare ecosystems also introduces significant challenges related to data quality, interoperability, algorithmic bias, explainability, ethics, and governance. This paper examines the progression from traditional digital health technologies to AI-enabled care models, highlighting key technological enablers, clinical applications, and system-level impacts. Furthermore, it explores the implications for healthcare professionals, patients, and policymakers, emphasizing the need for robust regulatory frameworks and human-centered AI design. Understanding this transition is critical for ensuring that AI-driven care augments clinical expertise, enhances patient trust, and delivers equitable and sustainable healthcare solutions.

Keywords : Digital health, Artificial intelligence in healthcare, AI-driven care, Clinical decision support systems, Machine learning, Predictive analytics, Personalized medicine, Precision healthcare, Health informatics, Electronic health records (EHRs), Big data in healthcare, Remote patient monitoring, Telemedicine, Automation in healthcare, Ethical AI, Explainable AI, Healthcare transformation, Patient-centered care, Interoperability, Data governance.

1. Introduction

Digital health technologies have reshaped the delivery of healthcare services, enabling remote consultation and monitoring, active patient engagement, lifestyle modification, and disease management. Despite their scalability and widespread adoption, most digital health tools remain isolated. The full value of digital health technologies is realized only when their data inputs or process outputs are harnessed by sophisticated artificial intelligence (AI) algorithms. Such AI-driven care offers greater efficiency, accuracy, and personalization — advantages that improve patient outcomes, alleviate clinician burnout, and stimulate health system resourcing. Consequently, the emergence and

evolution of AI models is now cited as the main reason behind the rapid scaling of digital health solutions.

Transitioning from isolated digital health technologies to AI-driven care requires careful consideration of the requisite data ecosystem and supportive enablement strategies. Concerted stakeholder action is necessary to establish the data standards, sources, architecture, and security measures that enable future success. Implementation guidance is also needed to find solutions that encompass the strategies, training, and governance structures that support AI adoption in clinical practice. Achievement of these milestones, all supported by a clear research agenda, sets the course from digital health to AI-driven care. The model aims to group



together similar observations based on distance metrics, often resulting in clusters of observations acting similarly.




Fig 1: The Role of AI in Healthcare

2. Digital Health Technologies: Definitions, Scope, and Current Landscape

Digital Health Technologies (DHTs) encompass information and communications technologies utilized in health and health care services. They can be classified into five major categories: telemedicine, mobile health, wearable devices, Electronic Health Records (EHRs), and health interoperability. Available evidence indicates that these tools can provide considerable advantages, yet they have limitations that hinder their impact. Consequently, recognizing the potential benefits while addressing the barriers to their adoption will enhance their effectiveness and reach. The analysis covers the current landscape of DHTs, illustrating the degree of uptake by companies and health-care services and systems, highlighting how DHTs help both patients and health personnel, and identifying potential weaknesses.

Although the offer of DHTs is wide and ever-increasing, uptake remains limited in comparison to overall technical capacity, partly due to market fragmentation and the absence

of validated medical use cases. The present architecture emphasizes the pivotal role of an underlying data ecosystem that enables both DHTs and artificial intelligence (AI). Such an approach highlights the need to go beyond simple pilot projects addressing isolated clinical challenges toward a comprehensive clinical and operating model that integrates DHTs with analytical and predictive AI capabilities. Failure to do so risks missing the considerable potential value that can be generated from combining the two technology families together in a carefully crafted ecosystem.



3. Foundations of Artificial Intelligence in Healthcare

Artificial intelligence (AI)—the simulation of human intelligence by computer systems—has gained phenomenal traction in the past few years. It encompasses several subdomains, including machine learning (ML), deep learning (DL), computer vision, and natural language processing. ML is a subset of AI in which systems can automatically learn from past experience without being explicitly programmed. Core components of ML are the data used to learn, the algorithms that capture the underlying relationships and the predictions made using the model. The rapid increase in the volume of data generated from various applications, particularly in the unstructured domain, has rekindled interest in DL, a subfield of ML. DL makes use of artificial neural networks that are sufficiently deep such that they possess multiple hidden layers. These networks are



trained using enormous volumes of data, often requiring substantial computational power to optimize the high number of parameters involved. NP-completeness theorem implies that an exhaustive search for the optimal parameter set is computationally infeasible; hence, stochastic optimization methods are commonly employed. In computer vision, CNNs, an ML technique modeled on the structure of the visual cortex, have ushered in a new era of accurate image classification, localization, and segmentation tasks.

AI is enabled by large volumes of high-quality data. The expression "garbage in, garbage out" reiterates the importance of the data used to build AI models: if the data is of poor quality, either due to noise or the presence of outlying observations, the predictions made by the model will also be faulty. AI models require repetitive examination of the data, both qualitatively and quantitatively, before feeding it to a modeling endeavor. Three types of learning approaches are currently in practice: supervised, unsupervised, and reinforcement learning. In supervised learning, two data sets are maintained: a training set to optimize the parameter and a test set to evaluate the performance of the model in predicting unseen data. The performance is generally assessed by accuracy (number of correct predictions/total predictions made), precision (number of true positives/number of predicted positives), and/or recall (number of true positives/number of actual positives). Test data is essential to assessing how well the model has captured the underlying relationships because, with training alone, the model can easily memorize the data points and yield perfect predictions. Unsupervised learning uses only one data set.

Equation 1: Supervised learning setup and why we split train/test

1.1 Notation

- Dataset: $\mathcal{D} = \{(x_i, y_i)\}_{i=1}^N$
- $x_i \in \mathbb{R}^d$ features (e.g., vitals from wearables, labs from EHR)

- $y_i \in \{0,1\}$ label (e.g., "will deteriorate in 24h")

We choose a model $f_\theta(x)$ with parameters θ .

1.2 Empirical risk minimization (training objective)

Pick a loss $\ell(\cdot, \cdot)$. The standard training objective:

$$\min_{\theta} \frac{1}{N} \sum_{i=1}^N \ell(f_{\theta}(x_i), y_i)$$

Why test set? If you evaluate only on the training set, the model can "memorize" data and appear perfect without actually learning patterns that transfer to new patients—exactly the generalization warning the paper makes .

4. Convergence: How Digital Health Technologies Enable AI-Driven Care

The arrival of artificial intelligence (AI) in healthcare generates enthusiasm. However, excitement is tempered by a mature understanding of the prerequisites for success: AI algorithms require sufficient high-quality data for effective modeling and execution. Such data ecosystems are partly being assembled through the deployment of Digital Health Technologies (DHTs)—telemedicine, mobile health, wearables, electronic health records, and associated elements. These tools collectively facilitate patient flow, communication, and limited monitoring; what is needed next is greater data integration and standardization, along with a deeper clinical role.

In AI-driven care, the interaction between DHTs and AI analytics must be symbiotic rather than auxiliary. This involves, for example, analyzing data from a real-time clinical support system or a disease management platform to derive complementary models that can then enhance the main decision-support tool; or observing and extracting information about hospital demand from sensor-based monitoring systems that would help deepen the predictive power of AI risk stratification models for in-patient care.



Examining the complete spectrum from DHTs to AI is critical; without overcoming intervening barriers and enablers, preventive and predictive approaches in care would remain stunted and underutilized.



Fig 2: Digital Health Technologies Enable AI-Driven Care

5. Architectural and Data Considerations for AI in Care

A reference architecture for AI-driven care encompasses stakeholders, component modules, data hierarchies, utilization domains, and distribution environments. Specific focus on data availability, characteristics, and utilization ensures clarity on gathering, harmonization, quality, and privacy. Consideration covers data sources, operational data and knowledge bases, and handling of bias during model training and prediction.

Developing AI-driven perimeterless healthcare requires data from diagnostic, prognostic, therapeutic, therapeutic evaluation, and internal control systems. Integration of HR, financial, and insurance data strengthens analytics for system sustainability and fault tolerant enhancement. AI analytics fulfill a support role, processing operational data and knowledge for timely approvals or alerts. Data harmonization leverages liaison services for operational or system closing, supported by business rules. Quality aspects include early validation, real-time monitoring, lineage tracking, contaminant detection, and test modification

facilitation. Architecture foundations bolster accuracy by implementing privacy-preserving techniques. Enabling infrastructure and logical platforms facilitate high availability and elasticity.

AI-driven perimeterless healthcare demands skill development for infrastructure construction and operational deployment. Building a basic training infrastructure accelerates model development and training, ultimately enhancing prediction accuracy. Detecting and mitigating bias within training and prediction datasets fosters system reliability.

Equation 2: Confusion matrix and metric derivations (Accuracy, Precision, Recall)

2.1 Confusion matrix definitions

For binary classification:

- **TP:** true positives = predicted positive and actually positive
- **FP:** false positives = predicted positive but actually negative
- **FN:** false negatives = predicted negative but actually positive
- **TN:** true negatives = predicted negative and actually negative

Total samples:

$$N = TP + FP + FN + TN$$

2.2 Accuracy derivation

“Correct predictions / all predictions”:

Correct predictions are TP and TN:

$$\text{Correct} = TP + TN$$

All predictions are N :



$$\text{Accuracy} = \frac{TP + TN}{TP + FP + FN + TN}$$

2.3 Precision derivation

Precision answers: “When the model predicts positive, how often is it correct?”

Predicted positives are $TP + FP$. Correct among them is TP :

$$\text{Precision} = \frac{TP}{TP + FP}$$

2.4 Recall derivation (Sensitivity)

Recall answers: “Among actual positives, how many did we catch?”

Actual positives are $TP + FN$. Caught positives are TP :

$$\text{Recall} = \frac{TP}{TP + FN}$$

2.5 F1-score (commonly used in healthcare)

Not explicitly in the paper, but directly related to precision/recall tradeoffs (very common in AI-driven care evaluation):

$$F1 = \frac{2}{\frac{1}{\text{Precision}} + \frac{1}{\text{Recall}}}$$

Derivation:


$$F1 = 2 \cdot \frac{\text{Precision} \cdot \text{Recall}}{\text{Precision} + \text{Recall}}$$

6. Clinical Applications of AI-Driven Care

Functional artificial intelligence can transform a myriad of areas within healthcare delivery, including diagnostics, medical imaging, risk stratification, clinical decision support systems, personalized treatment, and remote patient monitoring. In each case, AI analytics can enrich the

capabilities of the healthcare ecosystem and help deliver faster, safer, cheaper, and more effective care. However, only a few isolated AI application areas have achieved adoption at scale. This observation raises questions about the joint deployment of AI analytics and Digital Health Technologies tools, which can provide healthcare systems with the scale of data and operational synergies needed for sustained implementation in multiple domains.

Integrating Digital Health Technologies and AI analytics for the delivery of AI-driven care does not require breakthroughs in any of the underlying building blocks. Rather, it hinges on adequate investment and risk management in three key areas: deploying a comprehensive data ecosystem that serves as the backbone to feed AI analytics; establishing an architecture that harmonizes the operational workflows of Digital Health Technologies and AI analytics; and embracing a research agenda that supports the generation of evidence-grounded trust to dispel lingering concerns. A sample of clinical use cases illustrates the transformative value that can be unlocked by following a joint-deployment strategy while highlighting the potential benefits—as well as performance limitations—of the most complete and advanced implementations.





7. Evaluation, Evidence, and Regulatory Considerations

The evaluation of AI in Care must be rigorous and all-encompassing. AI-enabled tools for diagnostics, imaging, risk stratification, decision support, personalized therapy, and remote patient monitoring have advanced quickly, and prospective trials supporting their efficacy and utility have followed in fewer numbers than the speed of their introduction warrants. The regulatory landscape is evolving, generally keeping pace with the technology, and procedures are being defined to evaluate AI tools according to their strength of evidence and risk to the patient. The intersection of AI, safety, and essential requirements and standards is similar in many respects to that for medicines; the role of quality and quality of evidence in determining regulation is critical.

Gathering evidence to demonstrate that AI tools deliver on their promise and do so in a safe, effective, and understandable manner is complex and many-faceted. AI systems learn to perform tasks through the summary of evidence derived from example labelled datasets and therefore their introduction into clinical practice is associated with a set of uncertainties and risks of producing erroneous decisions that need to be considered during their development and adoption cycle. Appropriately designed evidence generation is critical, enabled through a combination of study design, prospective validation, and generalisation of evidence beyond the conditions of its derivation. The regulatory landscape for AI tools is developing, maintaining pace with the technology and ensuring that AI solutions can be presented for use with appropriate safety and quality demonstrations. Their deployment must take account of the best means of assessing safety, quality, transparency, and accountability for decision-making.




Fig 3: Evaluation, Evidence, and Regulatory Considerations of healthcare

8. Ethical, Legal, and Social Implications

Four ethical principles—beneficence, non-maleficence, autonomy, and justice—serve as the foundation for governance of humans, directing obligations towards others with care. AI exhibits beneficence to the Digital Health Technologies ecosystem in how it learns from and helps digital health tools. By supporting human decision-making, AI helps balance the other principles.

Privacy and confidentiality of patient health data is essential. Personal health information is sensitive and must be stored securely. Consent is usually recorded on paper or electronically during the first visit to a care institution. However, this method is insufficient for data sharing, as care must not only benefit individual patients but also their community and society, who require aggregate data for collective intelligence, evolving artificial systems, simulations, drug development, and investigation of low-incidence diseases. Patients need to be willing to “opt-out” of being actively involved in the data-sharing process using simple interfaces; otherwise, consent can be implicitly derived from data-sharing platforms complying with legal regulations.

Risk of harm—maleficence—is closely related to the validity of AI predictions and the risk–benefit analysis of the



decision-supporting task. Care institutions, however, remain responsible for the final decisions. Accountability, thus, rests with the operation and governance of the AI systems, ensuring AI algorithms are valid and explainable. It should not be attributed to the clinical healthcare professionals or organizations deploying AI systems, or to the patients who “use” the AI systems in the process of providing and receiving care.

Data ownership is one of the legal implications of AI. This issue needs to be resolved as soon as possible to ensure a proper balance among fairness, accountability, and transparency. The data is owned by the patients who acquired or produced it but cannot be owned by any third party without their consent. Preventing persons from being profiled based on their health may require legislation restricting data-sharing agreements unless aggregate data has enabled the profiling of a diverse community. Only access to the aggregated data should be available for a fee.

AI technologies are maturing rapidly with great promise but not without unintended consequences, such as script-kiddies – hackers using code made available by others but without knowledge of how it works; accelerating research criminally, cloud computing being abused for developing malicious software affordably; malware targeting healthcare servers; or batch attacks similar to spread. Equity is an inherent part of beneficence—it must be ensured that all communities gain with AI technology.

Equation 3: ROC curve equations (useful for “risk stratification” models)

Risk stratification is discussed as a clinical application area . ROC analysis is a standard way to evaluate such models.

Given a score $s(x) \in [0,1]$ and threshold t , predict positive if $s(x) \geq t$.

3.1 TPR and FPR

$$TPR(t) = \frac{TP(t)}{TP(t)+FN(t)} \quad (\text{same as Recall}) \quad FPR(t) = \frac{FP(t)}{FP(t)+TN(t)}$$

3.2 AUC (Area Under ROC)

AUC is the integral of TPR over FPR:

$$AUC = \int_0^1 TPR(FPR) d(FPR)$$

In discrete thresholds, trapezoidal approximation:

$$AUC \approx \sum_k \frac{TPR_k + TPR_{k+1}}{2} \cdot (FPR_{k+1} - FPR_k)$$

9. Implementation Pathways and Change Management

The transition from Digital Health Technologies (DHTs) to AI-driven care can be concisely delineated across nine implementation stages: stakeholder; data privacy; risk assessment; governance; training; workflow integration; monitoring; and continuous improvement. Stakeholder engagement must precede other activities, and an assessment of stakeholder interests, needs, concerns, and goals can establish an inclusive governance structure that fosters support for DHT development and supports adaptation of associated workflows. A privacy-preserving framework should be established to protect sensitive data central to DHTs. DHTs can provide an abundance of electronically stored data that serve diverse stakeholders within the care ecosystem, thereby raising concerns among system users about the quality, validity, and privacy of such data. Digital Health Technologies, AI-driven care, risk assessment, change management, and support. The implementation and change management of DHTs should, therefore, involve a careful risk assessment of potential benefits and vulnerabilities.



As illustrated previously, DHTs are effective in facilitating remote consultations, and these consultations can progressively integrate AI models supporting clinical decision-making. An evaluation of the expected impact of such tools will help identify key validators and detractors. Respondents within health ecosystems that have adopted DHTs will also require training that builds awareness of DHT data availability (a critical step toward AI adoption), use, and safety for clinical practice. These processes will together foster the development and deployment of AI models and APIs.

As mainstays of many care processes, however, their full value, value that shapes provision systems and operational processes based on artificial intelligence (AI) support and underpinning, is restricted.

Equation 4: Unsupervised learning and “distance metrics” for clustering

4.1 Euclidean distance (common baseline)

For two patient feature vectors $x_i, x_j \in \mathbb{R}^d$:

$$d(x_i, x_j) = \sqrt{\sum_{m=1}^d (x_{im} - x_{jm})^2}$$

4.2 Why squared distance shows up in optimization

Many clustering objectives use squared distances because it simplifies derivatives:

$$d^2(x_i, \mu_k) = \sum_{m=1}^d (x_{im} - \mu_{km})^2$$

4.3 K-means objective (typical example)

Assign each point to a cluster $c_i \in \{1, \dots, K\}$ with centroid μ_k :

$$\min_{\{c_i\}, \{\mu_k\}} \sum_{i=1}^N \|x_i - \mu_{c_i}\|^2$$

Centroid update derivation (key step)

For a fixed cluster k , minimize:

$$J(\mu_k) = \sum_{i:c_i=k} \|x_i - \mu_k\|^2$$

Expand:

$$J(\mu_k) = \sum_{i:c_i=k} \sum_{m=1}^d (x_{im} - \mu_{km})^2$$

Differentiate w.r.t. each component μ_{km} :

$$\frac{\partial J}{\partial \mu_{km}} = \sum_{i:c_i=k} 2(\mu_{km} - x_{im})$$

Set to zero:

$$\begin{aligned} \sum_{i:c_i=k} (\mu_{km} - x_{im}) &= 0 \Rightarrow n_k \mu_{km} = \sum_{i:c_i=k} x_{im} \Rightarrow \mu_{km} \\ &= \frac{1}{n_k} \sum_{i:c_i=k} x_{im} \end{aligned}$$

So the centroid is the **mean** of assigned points—hence “k-means”.

10. Future Directions and Research Agendas

The change from Digital Health Technologies (DHTs) to Artificial Intelligence (AI) in Care is a moving target. Existing discussions focus principally on DHTs in their own right, their value and shortfalls. Although increasingly seen as enablers of AI in Care, they are not the main focus. Yet, it is through the links to AI that DHTs genuinely offer major life science and care sector value and change potential. Understanding the path and work needed to secure that value and change is crucial. The development of care delivery and



operational systems focused on AI, and shaped by DHTs, requires attention to the types, sources, scaling and quality of data required, supporting technology infrastructure, attention and approach to bias issues, and governance structures, processes and policy. These considerations, and potential use cases, have been briefly outlined.

All forms of care delivery evolve over time. Some changes happen quickly, some take longer. Emerging technologies such as artificial intelligence (AI) shift the patterns of how things can be done and drive the sector in particular, sometimes unexpected, directions. However, the incorporation of novel technologies creates tension with existing systems based on older or different approaches. These underlying tensions can slow adoption of - and therefore many of the expected benefits of - the novel technologies. The integration of digital health technologies (DHTs) into existing care operations has, to date, occurred largely because such tools provide additional benefit through remote patient consultations or home based wellbeing and monitoring capabilities.

11. Conclusion

The transition from Digital Health Technologies to AI-driven care features major milestones supported by convergence of patients and clinicians using digital communication tools and health systems implementing enterprise-ready interoperability capabilities. Moving to AI-driven care creates opportunities to reduce healthcare costs, improve patient health outcomes, and curtail physician burnout. Navigating this transition requires addressing concerns about the ethical design of AI models, establishing a regulatory framework that ensures safe and effective use in patient care, and implementing these technologies in a manner aligned with values and actions of healthcare organizations and clinical teams.

The underlying research agenda is sized to guide the transition from digital health technologies to AI-driven care. Identifying a limited number of specific priorities creates a

coherent direction for the global research community. Addressing these questions will help stakeholders deliver and clinicians adopt a new set of digital health technologies that has the potential to improve healthcare delivery around the world. Key recommendations for practice provide the framework needed to undertake effective deployment.

12. References

1. Rivera, S. C., Liu, X., Chan, A.-W., Denniston, A. K., Calvert, M. J., & SPIRIT-AI and CONSORT-AI Working Group. (2020). Guidelines for clinical trial protocols for interventions involving artificial intelligence: The SPIRIT-AI extension. *The Lancet Digital Health*, 2(10), e549–e560.
2. Liu, X., Cruz Rivera, S., Moher, D., Calvert, M. J., Denniston, A. K., & CONSORT-AI Working Group. (2020). Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: The CONSORT-AI extension. *Nature Medicine*, 26, 1364–1374.
3. Kalisetty, S., & Inala, R. (2025). Designing Scalable Data Product Architectures With Agentic AI And ML: A Cross-Industry Study Of Cloud-Enabled Intelligence In Supply Chain, Insurance, Retail, Manufacturing, And Financial Services. *Metallurgical and Materials Engineering*, 86-98.
4. Topol, E. J. (2020). Welcoming new guidelines for AI clinical research. *Nature Medicine*, 26, 1318–1320.
5. Wynants, L., Van Calster, B., Collins, G. S., Riley, R. D., Heinze, G., Schuit, E., Bonten, M. M. J., Dahly, D. L., Damen, J. A. A., Debray, T. P. A., de Jong, V. M. T., De Vos, M., Dhiman, P., Haller, M. C., Harhay, M. O., Henckaerts, L., Heus, P., Kammer, M., Kreuzberger, N., ... van Smeden, M. (2020). Prediction models for diagnosis and prognosis of COVID-19: Systematic review and critical appraisal. *BMJ*, 369, m1328.



6. Panch, T., Mattie, H., & Atun, R. (2020). Artificial intelligence and algorithmic bias: Implications for health systems. *Journal of Global Health*, 10(2), 020353.
7. Davenport, T., & Kalakota, R. (2020). The potential for artificial intelligence in healthcare. *Future Healthcare Journal*, 6(2), 94–98.
8. Paleti, S., Baliyan, M., Aitha, A. R., Reddy, B. A., Bhadauria, G. S., & Sing, S. A. (2025, August). Graph—LSTM Hybrid Model for Improving Fraud Detection Accuracy in E-Commerce Financial Services. In 2025 2nd International Conference on Intelligent Algorithms for Computational Intelligence Systems (IACIS) (pp. 1-6). IEEE.
9. Meda, R. (2025). Dynamic Territory Management and Account Segmentation using Machine Learning: Strategies for Maximizing Sales Efficiency in a US Zonal Network. *EKSPLORIUM-BULETIN PUSAT TEKNOLOGI BAHAN GALIAN NUKLIR*, 46(1), 634-653.
10. Yu, K.-H., Beam, A. L., & Kohane, I. S. (2018). Artificial intelligence in healthcare. *Nature Biomedical Engineering*, 2, 719–731.
11. Yin, J., Ngiam, K. Y., & Teo, H. H. (2021). Role of artificial intelligence applications in real-life clinical practice: Systematic review. *Journal of Medical Internet Research*, 23(4), e25759.
12. Kueper, J. K., Terry, A. L., Li, J., & Liddy, C. (2021). Artificial intelligence and machine learning in primary care: A scoping review. *BMC Primary Care*, 22, 191.
13. Richardson, J. P., Smith, C., Curtis, S., Watson, S., Zhu, X., Barry, B., & Sharp, R. R. (2021). Patient apprehensions about the use of artificial intelligence in healthcare. *NPJ Digital Medicine*, 4, 140.
14. Blease, C., Kaptchuk, T. J., Bernstein, M. H., Mandl, K. D., Halamka, J. D., & DesRoches, C. M. (2021). Artificial intelligence and the future of primary care: Exploratory qualitative study of UK general practitioners' views. *Journal of Medical Internet Research*, 23(3), e23276.
15. Lebcir, I., Mageswari, S. D., Bhosale, Y. H., Nagubandi, A. R., & Mahabooba, M. (2025). Agile Strategic Management in the Age of Disruption: Leveraging AI and Data Analytics for Competitive Advantage. *Advances in Consumer Research*, 2(6), 2581.
16. Young, A. T., Ammerman, A., & Stankovic, J. A. (2021). Artificial intelligence in healthcare: A systematic review of the literature. *Journal of Healthcare Engineering*, 2021, 1–15.
17. Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J. (2022). AI in health and medicine. *Nature Medicine*, 28, 31–38.
18. Acosta, J. N., Falcone, G. J., Rajpurkar, P., & Topol, E. J. (2022). Multimodal biomedical AI. *Nature Medicine*, 28, 1773–1784.
19. Martinez-Martin, N., Greely, H. T., & Cho, M. K. (2022). Ethical challenges in the use of artificial intelligence in healthcare. *Journal of Medical Ethics*, 48(10), 683–688.
20. Meda, R. (2025). AI-Driven Demand and Supply Forecasting Models for Enhanced Sales Performance Management: A Case Study of a Four-Zone Structure in the United States. *Metallurgical and Materials Engineering*, 1480-1500.
21. Martinez-Millana, A., Saiz, J., Fernandez-Llatas, C., & Traver, V. (2022). Artificial intelligence and its impact on the domains of universal health coverage, health emergencies and health promotion: An overview of systematic reviews. *International Journal of Medical Informatics*, 166, 104855.
22. Kelly, C. J., Karthikesalingam, A., Suleyman, M., Corrado, G., & King, D. (2019). Key challenges for delivering clinical impact with artificial intelligence. *BMC Medicine*, 17, 195.
23. Saif-Ur-Rahman, K. M., Islam, M. S., Alaboson, J., Ola, O., Hasan, I., Islam, N., Mainali, S., Martina, T., Silenga, E., Muyangana, M., & Joarder, T. (2023). Artificial intelligence and digital health in improving primary health care service delivery in low- and middle-income countries: A systematic review. *Journal of Evidence-Based Medicine*, 16(3), 303–320.
24. Thirunavukarasu, A. J., Ting, D. S. J., Elangovan, K., Gutierrez, L., Tan, T. F., & Ting, D. S. W. (2023).



- Large language models in medicine. *Nature Medicine*, 29, 1930–1940.
24. Wubineh, B. Z., Deriba, F. G., & Woldeyohannis, M. M. (2024). Exploring the opportunities and challenges of implementing artificial intelligence in healthcare: A systematic literature review. *Urologic Oncology: Seminars and Original Investigations*, 42(3), 48–56.
 25. Han, R., Acosta, J. N., Shakeri, Z., Ioannidis, J. P. A., & Topol, E. J. (2024). Randomised controlled trials evaluating artificial intelligence in clinical practice: A scoping review. *The Lancet Digital Health*, 6(5), e367–e373.
 26. Chen, S., Guevara, M., Moningi, S., Hoebers, F., Elhalawani, H., & colleagues. (2024). The effect of using a large language model to respond to patient messages. *The Lancet Digital Health*, 6(6), e379–e381.
 27. Varghese, C., Harrison, E. M., O’Grady, G., & Topol, E. J. (2024). Artificial intelligence in surgery. *Nature Medicine*, 30, 1257–1268.
 28. Goldberg, C. B., Adams, L., Blumenthal, D., & colleagues. (2024). Patient-centered artificial intelligence in healthcare: Opportunities and challenges. *Nature Medicine*, 30, 1–8.
 29. Kumar, K. M., Parasar, A., Walia, A., Inala, R., & Thulasimani, T. (2025, August). Enhancing Risk Management Strategies in Financial Institutions Using CNN and Support Vector Regression. In *2025 5th Asian Conference on Innovation in Technology (ASIANCON)* (pp. 1-6). IEEE.
 30. Waisberg, E., Ong, J., Masalkhi, M., Kamran, S. A., Zaman, N., Sarker, P., Tavakkoli, A., & Tegnelli, E. (2024). GPT-4 and artificial intelligence in medicine: A systematic review of the emerging evidence. *Journal of Medical Internet Research*, 26, e52295.
 31. Teo, Z. L., Thirunavukarasu, A. J., Elangovan, K., Cheng, H., Moova, P., Soetikno, B., Nielsen, C., Pollreis, A., Ting, D. S. J., Morris, R. J. T., Shah, N. H., Langlotz, C. P., & Ting, D. S. W. (2025). Generative artificial intelligence in medicine. *Nature Medicine*, 31, 3270–3282.
 32. Mathias, R., Vasey, B., Chalkidou, A., Riedemann, L., Melvin, T., & Gilbert, S. (2025). Safe AI-enabled digital health technologies need built-in open feedback. *Nature Medicine*, 31(2), 370–375.
 33. Webster, P. (2023). Six ways large language models are changing healthcare. *Nature Medicine*, 29, 2969–2971.
 34. The Lancet Digital Health. (2024). Large language models: A new chapter in digital health. *The Lancet Digital Health*, 6(1), e1.
 35. Wubineh, B. Z., Deriba, F. G., & Woldeyohannis, M. M. (2024). Exploring the opportunities and challenges of implementing artificial intelligence in healthcare: A systematic literature review. *Urologic Oncology: Seminars and Original Investigations*, 42(3), 48–56.